



Evaluation of the implementation of the Xpert® MTB/RIF assay in Fiji

A. Gounder,¹ S. Gounder,¹ S. A. Reid²

<http://dx.doi.org/10.5588/pha.14.0025>

Setting: All Xpert® MTB/RIF tests performed in the three TB (tuberculosis) treatment centres in Fiji from June 2012 to February 2013.

Objectives: To determine 1) the number of Xpert tests performed in each centre, 2) the association between sputum quality and Xpert results, 3) the agreement of Xpert with acid-fast bacilli (AFB) smear microscopy and TB culture and 4) error rates.

Design: Retrospective review of records.

Results: A total of 415 Xpert tests were performed in the study period. *Mycobacterium tuberculosis* was detected in 69 (16.6%) samples. No rifampicin resistance was detected. *M. tuberculosis* was detected from 60 (18.7%) good-quality sputum samples. A total of 43 (10.4%) errors occurred during this period. *M. tuberculosis* was detected in 10 (2.9%) smear-negative specimens. There was a substantial and an almost perfect agreement between Xpert and AFB microscopy ($\kappa = 0.793$) and culture results ($\kappa = 0.818$), respectively.

Conclusion: Although a good correlation between Xpert and the two tests were shown in the study, Xpert should not replace the routine first-line TB diagnostic tests used in Fiji for reasons related to logistics and sustainability. A further evaluation of the assay's performance is required over a longer time period to gauge its diagnostic value in detecting smear-negative, Xpert-positive cases in Fiji.

Smear microscopy for acid-fast bacilli (AFB) is the standard tool for the diagnosis of pulmonary tuberculosis (TB) caused by *Mycobacterium tuberculosis* in Fiji. Sputum culture using Ogawa medium is used to complement AFB smear microscopy, especially among smear-negative specimens. Diagnosis of TB in Fiji is constrained by the low sensitivity of AFB smear microscopy, the inability to determine drug susceptibility and the variability in operator performance. In addition, solid culture takes about 6–8 weeks to obtain a result, and significant numbers of cultures become contaminated.

In June 2012, the Fiji National TB Programme introduced the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) at the three anti-tuberculosis treatment centres in Fiji to increase case detection rates and investigate rifampicin (RMP) resistance. Xpert is a cartridge-based, fully automated, real-time nucleic acid amplification test for rapid detection of *M. tuberculosis* and RMP resistance, which is a good marker for multi-drug-resistant TB (MDR-TB). Results are obtained within 2 h, which helps reduce the length of hospitalisation and the number of deaths due to TB.¹ The re-

sults from a recent study showed that the mean time to TB detection was <1 day for Xpert, whereas smear microscopy requires a day.²

A number of issues have been identified while implementing Xpert in Fiji, and this requires further investigation. These included a significant number of errors during sample testing and issues related to the short shelf-life of the kits. Similar issues were identified by the World Health Organization in 2011.² Fiji now has three diagnostic tools for TB, with a degree of overlap in their functionality. There is therefore a need to understand the diagnostic value of Xpert and its level of agreement with AFB smear microscopy and TB culture in Fiji. It was also important to compare the performance of the three TB treatment centres and the quality of sputum to determine if these had contributed to the errors. We therefore conducted this study to provide answers to some of these questions and to prevent the previously mentioned constraints from recurring.

METHODS

This was a retrospective study using data from all samples tested with Xpert in the three anti-tuberculosis treatment centres in Fiji from June 2012 to February 2013.

Setting

Fiji is an archipelago of more than 322 islands which lies at the heart of the Pacific Ocean. The population of Fiji is approximately 837 271,³ 87% of whom reside in the two major islands, Viti Levu and Vanua Levu. There are three anti-tuberculosis treatment centres and four AFB smear microscopy laboratories in Fiji. Tuberculosis culture on Ogawa medium is only performed by the Daulako Mycobacterium Reference Laboratory (DMRL), located in P J Twomey Hospital in the capital, Suva. Xpert testing is performed at the DMRL, Lautoka and Labasa Hospitals. The National Tuberculosis Programme (NTP) criteria for the use of Xpert include patients who are symptomatic but AFB smear-negative (on three specimens), AFB smear-positive but failed to convert after 3 months of the intensive phase of treatment, relapses after apparently successful treatment, human immunodeficiency virus (HIV) positive patients and cases from high multi-drug-resistant TB burden countries.

Data variables, data collection instrument

Data for Xpert testing performed between June 2012 and February 2013 were extracted from the AFB smear microscopy register in the laboratories in each of the

AFFILIATIONS

- 1 National Tuberculosis Program, Ministry of Health, Suva, Fiji
- 2 School of Population Health, The University of Queensland, Brisbane, Queensland, Australia

CORRESPONDENCE

Archna Gounder
P J Twomey Hospital
Ministry of Health
Suva, Fiji
Tel: (+679) 993 0878
e-mail: archgounder@gmail.com

KEY WORDS

evaluation; Xpert® MTB/RIF; *Mycobacterium tuberculosis*; rifampicin

Received 14 March 2014
Accepted 28 July 2014

PHA2014;4(3):179–183
© 2014 The Union

TABLE 1 Characteristics of sputum specimens tested using Xpert® MTB/RIF at three anti-tuberculosis treatment centres, Fiji, June 2012–February 2013

Variables	Total (<i>n</i> = 415) <i>n</i> (%)	Xpert results		
		<i>M. tuberculosis</i> detected <i>n</i> (%)	<i>M. tuberculosis</i> not detected <i>n</i> (%)	Error <i>n</i> (%)
Testing laboratory				
DMRL	164 (39.5)	32 (19.5)	113 (68.9)	19 (11.6)
Lautoka	114 (27.5)	21 (18.4)	81 (71.1)	12 (10.5)
Labasa	137 (33.0)	16 (11.7)	109 (79.6)	12 (8.8)
Sputum quality				
Good	318 (77.3)	60 (18.7)	227 (70.7)	34 (10.6)
Poor	94 (22.7)	9 (9.6)	76 (80.9)	9 (9.6)
AFB smear result				
AFB 3+	37 (8.9)	34 (91.9)	0 (0)	3 (8.1)
AFB 2+	8 (1.9)	6 (75.0)	0 (0)	2 (25.0)
AFB 1+	18 (4.3)	16 (88.9)	1 (5.6)	1 (5.6)
Scanty not quantified	1 (0.2)	0	0 (0)	1 (100)
Scanty and quantified	9 (2.2)	3 (33.3)	2 (22.2)	4 (44.4)
Negative	342 (82.4)	10 (2.9)	300 (87.7)	32 (9.4)
Culture result				
<i>Mycobacterium</i> spp. isolated	55 (13.3)	41 (74.5)	3 (5.5)	11 (20.0)
No growth	152 (36.6)	10 (6.6)	135 (88.8)	7 (4.6)
Contaminated	10 (2.4)	1 (10.0)	8 (80)	1 (10.0)
Not done	198 (47.7)	17 (8.6)	157 (79.3)	24 (12.1)

DMRL = Daulako Mycobacterium Reference Laboratory; AFB = acid-fast bacilli.

three anti-tuberculosis treatment centres. Data for each variable were manually collected into a structured proforma. Exposure variables for each sputum specimen included quality of sputum (poor or good), age, sex and testing laboratory. Quality of sputum was classified as follows: good = blood-stained, mucoid or purulent; poor = thin, watery or mainly composed of bubbles and saliva. Outcome variables included Xpert, smear and culture results. AFB smear microscopy results were classified according to the International Union for Tuberculosis and Lung Disease (The Union), Paris, France.⁴

Analysis and statistics

Data were collected manually and double-entered into an electronic database (EpiData, version 3.1, EpiData Association, Odense, Denmark). A uniform data entry file was developed using EpiData Entry 3.1. Errors in data entry were detected by comparing the duplicate EpiData files for any discordance. Corrections were made by cross-checking with the proformas to produce a final data set.

Data were first analysed using descriptive exploratory statistics. The statistical significance of observed differences between the proportions of determinants and outcome variables was determined using the χ^2 test at a 95% confidence level using EpiAnalysis (EpiData Association). The level of agreement between tests (κ), sensitivity and specificity and their binomial 95% confidence intervals (CIs) for Xpert using culture and AFB smear microscopy, were calculated using WinEpi.⁵

Ethics approval

Ethics approval was obtained from the Ethics Advisory Group (EAG) of The Union, the National Health Re-

search Committee, Suva, and the Fiji National Research Ethics Review Committee, Suva, Fiji.

RESULTS

The results from testing 415 sputum specimens using Xpert are presented in Table 1. The majority of the samples were tested at the DMRL (*n* = 164, 39.5%), followed by the Western (*n* = 114, 27.5%) and Northern Divisions (*n* = 137, 33.0%).

Sputum quality

A total of 94 (22.7%) sputum specimens were of poor quality. *M. tuberculosis* was detected in 60 (18.7%) good quality and 9 (9.6%) poor quality sputum specimens using Xpert. The overall error rate was similar in good (10.3%, 95%CI 7.3–14.3) and poor quality (9.6%, 95%CI 4.7–17.8) sputum specimens. There was a significantly higher positivity rate in good than in poor quality specimens (20.9%, 95%CI 16.4–26.2 vs. 10.6%, 95%CI 5.3–19.6, *P* < 0.05).

AFB smear microscopy

M. tuberculosis was detected in 10 (2.9%) AFB smear-negative specimens. Three (27.8%) of the specimens were smear-positive but with no *M. tuberculosis* detected using Xpert. Xpert errors were detected in 34 (10.6%) AFB smear-negative specimens and in 9 (9.6%) AFB smear-positive specimens.

The sensitivity and specificity of Xpert using microscopy as the gold standard was respectively 80.8% (95%CI 71.8–89.9) and 96.8% (95%CI 94.8–98.7). There was substantial agreement between microscopy and Xpert results (κ = 0.793).

ACKNOWLEDGEMENTS

This research was conducted through the Structured Operational Research and Training Initiative (SORT IT). The training was run in Fiji by the College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji and the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France. Additional support for running the course was provided by the Public Health Division of the Secretariat of the Pacific Community (SPC), Nouméa, New Caledonia; Centre for International Child Health (ICRC), the University of Melbourne, Melbourne, VIC, Australia; School of Population Health, University of Queensland, Brisbane, QLD, Australia; Regional Public Health, Hutt Valley District Health Board, Lower Hutt, New Zealand; and the National TB Programme, Fiji Ministry of Health, Suva, Fiji. Funding for the course was provided by the Global Fund to Fight AIDS, TB and Malaria, Geneva, Switzerland, with co-funding from The Union; the Special Programme for Research and Training in Tropical Diseases; Public Health Division of the SPC, Nouméa, New Caledonia; ICRC, the University of Melbourne, Melbourne, VIC, Australia; School of Population Health, University of Queensland, Brisbane, QLD, Australia. Conflict of interest: none declared.

TABLE 2 Number and type of error recorded after testing sputum specimens for the presence of *Mycobacterium tuberculosis* using Xpert® MTB/RIF in three laboratories, Fiji, June 2012–February 2013

Error code*	DMRL <i>n</i> (%)	Lautoka Hospital <i>n</i> (%)	Labasa Hospital <i>n</i> (%)	Total <i>n</i>
1018	1 (100.0)	0 (0)	0 (0)	1
2008	4 (44.4)	3 (33.3)	2 (22.3)	9
5006	1 (100.0)	0 (0)	0 (0)	1
5007	3 (30.0)	5 (50.0)	2 (20.0)	10
5011	3 (60.0)	1 (20.0)	1 (20.0)	5
Invalid	2 (33.3)	3 (33.3)	1 (16.4)	6
No result	5 (45.5)	0 (0)	6 (54.5)	11
Total	19	12	12	43

*Xpert error results were defined according to the manufacturer's specifications, as follows: 5006/5007/5008 = failure of probe check control; mainly associated with sputum viscosity and/or volume, incorrect filling of reaction tube or detection of probe integrity problem; 5011 = loss of tube pressure; 2008 = pressure exceeds maximum pressure acceptable, or failure of Xpert module, mostly caused by sample viscosity; 1018 = valve positioning error; invalid result = sample processing control, an inbuilt control, fails and the polymerase chain reaction was inhibited due to the presence of pus, blood or food particles; no result = insufficient data were collected because the test was stopped voluntarily or due to electrical failure.⁵

TB culture

Of the 217 (52.3%) sputum specimens tested using both Xpert and culture, 10 (2.4%) were contaminated; 3 (5.5%) specimens were Xpert-negative but culture-positive. The sensitivity and specificity using culture as the gold standard were respectively 93.2% (95%CI 85.7–100.6) and 93.1% (95%CI 89.0–97.2). There was almost perfect agreement between culture and Xpert results ($\kappa = 0.818$).

Errors

We detected a total of 43 (10.4%) errors. There were no significant differences in error rates in testing conducted in the three divisions. The results of different error types are presented in Table 2. Error '5007' ($n = 10$) and 'no result' ($n = 11$) were the most common errors recorded. DMRL recorded a high number of errors due to the large number of samples tested. The number of errors detected at the Lautoka and Labasa Hospitals was the same ($n = 12$).

DISCUSSION

This is the first study in Fiji to evaluate the implementation of Xpert for TB diagnosis. Fiji does not currently perform routine drug susceptibility testing (DST) for *M. tuberculosis* isolates. In cases where DST is needed, culture isolates on Ogawa are sent to a reference laboratory in Australia for testing. To date, RMP resistance has not been detected in any *M. tuberculosis* culture isolates from Fiji,⁶ and no RMP resistance was detected using Xpert during the study period.

One of the most significant logistical issues experienced during implementation was the overestimation of Xpert cartridge requirements in the implementation phase, and the Xpert cartridges were obtained in a single shipment. In addition, only a small number of samples met the algorithm developed by the NTP for Xpert testing. Furthermore, as the purpose of the new test and the structure of the implementation phase were not communicated fully to the clinical staff in the hospitals in Fiji, except for those in the TB clinics, only a small number of requests came from doctors in the divisional hospitals, which have a large daily turnover of patients. Sputum samples were only submitted if the microscopy results were indeterminate. The end result was that about 30% of the 600 cartridges were discarded due to their short

shelf-life. This was followed by a lapse of 7 months before the second batch of test cartridges arrived. This suggests that the Fiji NTP needs both to revise its procurement guidelines to improve stock management for newly introduced tests and also to initiate training in Xpert and its value for medical officers, not only at the TB clinics but at all the other facilities in Fiji. In a similar study by Creswell et al. evaluating data from nine countries, cartridges were shipped in different batches to avoid waste.⁷ In addition, NTP guidelines for Xpert in the nine countries were more focused on detecting drug resistance than on active case finding.⁷

It is interesting to note that a high number of errors occurred in good quality sputum. We also documented high rates of *M. tuberculosis* in good quality sputum specimens. Use of good quality sputum for Xpert testing was also recommended in a study in Zimbabwe.⁸ Rectifying this error was therefore a priority for Fiji. A similar problem was observed in India after Xpert was decentralised to a lower level of the health system.⁹ The majority of the failures in this case were caused by the high viscosity of good quality sputum samples. It was therefore recommended that sputum specimens with high viscosity be incubated for an additional 10 min before Xpert testing.⁹

Xpert correctly identified *M. tuberculosis* in 80% of the AFB smear-positive specimens, indicating that it reliably identifies the presence of *M. tuberculosis* in patients with a high bacterial load. In Fiji's low-prevalence setting, the number of new Xpert-positive, smear-negative specimens was low ($n = 3$, 0.9%). In such a low-burden setting, the NTP needs to re-evaluate its stringent algorithm for Xpert testing. In South Africa, the time to diagnosis increased by almost two-fold when Xpert (82%) was used for diagnosis followed by smear microscopy, culture and clinical observations (44%).¹⁰ In the multicentre study by Creswell et al., Xpert was used as a second test for smear-negative cases in the nine countries studied.⁷ It is important to note that Xpert can also be performed for highly suspected clinical cases.

Of the 10 cases that were AFB smear-negative but Xpert-positive for *M. tuberculosis*, 3 were new cases and 7 were follow-up patients who were on anti-tuberculosis medication at the time. The seven follow-up specimens were tested using Xpert only to check for any RMP resistance, as Xpert is not used to monitor treatment.

The almost perfect agreement between Xpert and culture is re-

assuring, as it suggests that culture is being performed relatively efficiently. Surprisingly, Xpert was unable to detect two AFB-positive smears as positive, although these were confirmed as positive on culture. The two cases were follow-up patients. This result was similar to a study in Uganda, where it was documented that the assay was unable to detect *M. tuberculosis* in 20.6% of children with culture-confirmed pulmonary TB.¹¹ Similar results were found in a study performed in two hospitals in Cape Town, South Africa, where nearly a quarter of the children were *M. tuberculosis*-negative using Xpert but positive using culture.¹² A thorough clinical assessment is therefore important in introducing anti-tuberculosis treatment in Xpert-negative patients. Culture thus remains the gold standard for the diagnosis of TB, as it has the ability to grow low concentrations of bacteria from sputum isolates, which can be used to perform DST and phenotyping.

Using Xpert, 43 (10.4%) errors were detected. The error code 'no result' ($n = 11$, 26%) indicates a power failure; however, in this case no power failure was recorded in the three centres and all were using an uninterrupted power supply. Furthermore, although Cepheid recommends that Xpert machines be calibrated after 2000 cycles or after 1 year,⁵ whichever comes first, calibration had still not been performed 1 year after installation. In the early programmatic implementation of Xpert in nine countries, the assay was repeated if it failed in the first run.⁷

As data from all Xpert tests were acquired from all the three centres in Fiji, this study is therefore representative of the nationwide implementation of Xpert. AFB microscopy and culture results were also extracted for comparison purposes, and the data collected were validated by cross-checking with the electronic data stored in Xpert.

The age of the samples could not be analysed due to unavailability of the date of specimen collection. Although the dates recorded in the laboratory registers indicated when the sample had been received by the laboratory, they could not be taken as date of collection, as the samples were referred from different health facilities. We could not therefore determine whether the age of the sample affected Xpert results, and particularly the errors. However, in India, regional distribution, demographic profile and level of decentralisation were not related to test failures.⁹ Nevertheless, it is still recommended that all health facilities follow national guidelines and correctly identify the date of collection both in the request form and on the specimen container before sending them to the test laboratory, both for Xpert testing and for culture, where the risk of contamination is high.

As Fiji will soon be introducing liquid culture on MGIT™ (BD,

Sparks, MD, USA), further research with larger samples and comparisons of the four tests can be carried out.

CONCLUSION

This study shows a good correlation between Xpert and the two tests routinely used for TB diagnosis in Fiji. However, it also outlines a number of manageable obstacles to implementation. Further evaluations of Xpert are required to re-evaluate the performance of the test in detecting smear-negative, Xpert-positive cases over a longer time period. Because of logistical and sustainability issues, Xpert cannot replace routine first-line diagnostic tests in Fiji.

References

- 1 Arzu N Z, Sezai T, Cengiz C. Evaluation of the GeneXpert® MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. *J Clin Microbiol* 2011; 49: 4138–4141.
- 2 World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/Rif System (Policy Statement). WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011.
- 3 Fiji Island Bureau of Statistics. Fiji Population Census. Suva, Fiji: Bureau of Statistics, 2007.
- 4 International Union Against Tuberculosis and Lung Disease. Technical guideline: sputum examination for tuberculosis by direct microscopy in low income countries. Microscopic examination of sputum smears. Paris, France: The Union, 2000: p 14.
- 5 de Blas I, Ruiz-Zarzuola I, Vallejo A. WinEpi: working in epidemiology. An online epidemiological tool. Zaragoza, Spain: Facultad de Veterinaria, Universidad de Zaragoza, 2006. <http://www.winepi.net/> Accessed August 2014.
- 6 World Health Organization. Fiji tuberculosis profile 2012. Geneva, Switzerland: WHO, 2014. https://extranet.who.int/sree/Reports?op=Replet&name=/WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfile&ISO2=FJ&out-type=html. Accessed August 2014.
- 7 Creswell J, Codlin A, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. *BMC Infect Dis* 2014; 14: 2.
- 8 Chemhuru M, Duka M, Bernardin Nanan-n'zeth K J, et al. Implementation of Xpert® MTB/RIF assay in Buhera District, Zimbabwe: lessons learned. Paris, France: Médecins Sans Frontières, 2011.
- 9 Raizada N, Sachdeva K S, Sreenivas A, et al. Feasibility of decentralised deployment of Xpert® MTB/RIF test at lower level of health system in India. *PLOS ONE* 2014; 9: e89301.
- 10 Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert® MTB/RIF in South Africa. *PLOS ONE* 2012; 7: e36966.
- 11 Sekadde M P, Wobudeya E, Joloba M, et al. Evaluation of the Xpert® MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. *BMC Infect Dis* 2013; 13: 133.
- 12 Nicol M, Workman L, Isaacs W, Munro J, Black F, Eley B. Accuracy of the Xpert® MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. *Lancet Infect Dis* 2011; 11: 819–824.

Contexte : Tous les tests Xpert® MTB/RIF réalisés dans les trois centres de traitement anti-tuberculeux aux Fidji entre juin 2012 et février 2013.

Objectifs : Déterminer 1) le nombre de tests Xpert réalisés dans chaque centre, 2) l'association entre la qualité des crachats et le résultat du test Xpert, 3) l'accord entre Xpert et la microscopie des crachats acido alcoolique résistant (AFB) et la culture, et 4) le taux d'erreurs.

Schéma : Revue rétrospective de dossiers.

Résultats : Un total de 415 tests Xpert a été réalisé pendant la période d'étude. *Mycobacterium tuberculosis* a été détecté dans 69 (16,6%) échantillons. Aucune résistance à la rifampicine n'a été décelée. *M. tuberculosis* a été identifié dans 60 (18,7%) échantillons de crachats de bonne qualité. Un total de 43 (10,4%) erreurs sont

survenues pendant la période d'étude. *M. tuberculosis* a été identifié dans 10 (2,9%) spécimens à frottis négatif. Il y a eu une concordance substantielle et presque parfaite entre les résultats du Xpert et ceux de la microscopie AFB ($\kappa = 0,793$) et de la culture ($\kappa = 0,818$), respectivement.

Conclusion : En dépit de la bonne corrélation entre Xpert et les deux autres tests mise en évidence dans l'étude, Xpert ne peut toujours pas remplacer les tests de diagnostic de routine utilisés en première intention aux Fidji, en raison de contraintes logistiques et de problèmes de pérennité. Il est nécessaire de réaliser une évaluation ultérieure de la performance de ce test sur une période plus longue afin de mesurer sa valeur diagnostique dans la détection de cas à frottis négatif, Xpert positif aux Fidji.

Marco de referencia: Todas las pruebas Xpert® MTB/RIF realizadas en los tres centros de atención de la tuberculosis (TB) de Fiji entre junio del 2012 y febrero del 2013.

Objetivos: Obtener la siguiente información: 1) el número de pruebas Xpert realizadas en cada centro; 2) la asociación entre la calidad de la muestra de esputo y el resultado de la prueba Xpert; 3) la concordancia de los resultados de esta prueba con la baciloscopia y el cultivo para *Mycobacterium tuberculosis*; y 4) las tasas de error de la prueba.

Método: Fue este un estudio retrospectivo a partir de las historias clínicas.

Resultados: Durante el período del estudio se practicaron 415 pruebas Xpert. Esta prueba aportó un resultado positivo para *M. tuberculosis* en 69 muestras de esputo (16,6%). No se encontró resistencia a rifamicina. Se detectó *M. tuberculosis* en 60 de muestras

de esputo de buena calidad (18,7%). Se registraron 43 resultados de error de la prueba durante el período estudiado (10,4%). La prueba detectó *M. tuberculosis* en 10 muestras con baciloscopia negativa (2,9%). La concordancia de los resultados de la prueba Xpert con la baciloscopia del esputo fue notable ($\kappa = 0,793$) y casi perfecta con los resultados del cultivo ($\kappa = 0,818$).

Conclusión: Si bien en el presente estudio la prueba Xpert exhibió una buena correlación con los métodos de referencia, todavía no puede remplazar las pruebas sistemáticas de elección en el diagnóstico de la TB en Fiji por razones operativas y de sostenibilidad. Es necesario realizar nuevos estudios de rendimiento diagnóstico durante un período más prolongado, a fin de estimar su utilidad diagnóstica en los casos que presentan una baciloscopia negativa y una prueba Xpert positiva en Fiji.